Pharma BD Deal Intelligence
Merck & Co. Inc. / Peloton Therapeutics Inc.
2019 · Acquisition/Merger · $2.2B · Complete
Announcement Sentiment
88
Strongly positive
Outcome Score
88
Worked — the deal delivered on its rationale.
Merck acquired privately held Peloton Therapeutics for up to $2.2 billion ($1.05 billion upfront plus $1.15 billion in milestones), gaining PT2977 (belzutifan/Welireg), a novel oral HIF-2α inhibitor in late-stage development for renal cell carcinoma.
Key facts
Announced May 21, 2019 Closed Jul 31, 2019 Deal value $2.2B Deal type Acquisition/Merger Therapeutic area Oncology Indications Renal Cell Carcinoma Key assets PT2977 (belzutifan/Welireg), HIF-2α inhibitor platform Mechanism HIF-2α (hypoxia-inducible factor 2-alpha) inhibitor
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
The Pharma Closeout — Deal Intelligence Database.
Announcement Sentiment and Outcome Score from sourced facts.Home ·
Deals ·
Methodology ·
About